PTM Therapeutics focuses on identifying disease-specific targets for therapeutic antibodies by leveraging Post Translational Modifications (PTMs). The company aims to develop new therapeutics for chronic diseases and cancer, addressing the need for more precise treatment options in these areas.
Funding
Funding not disclosed
Founders
Product
Problem
Developing targeted therapeutics for chronic diseases and cancer is challenging due to the limited availability of disease-specific targets. Traditional drug discovery approaches often lack the precision needed to selectively target diseased cells, leading to potential off-target effects and reduced efficacy.
Solution
PTM Therapeutics leverages post-translational modifications (PTMs) to identify disease-specific targets for therapeutic antibody development. By focusing on PTMs, the company aims to create more precise and effective therapeutics for chronic diseases and cancer. This approach allows for the development of antibodies that selectively bind to disease-specific PTMs, minimizing off-target effects and maximizing therapeutic impact. The company is dedicated to discovering novel targets and developing innovative treatments to improve human healthspan and well-being.
Target Audience
The primary target audience includes individuals suffering from chronic diseases and cancer, as well as healthcare providers seeking more precise and effective treatment options.
Features
- Identification of disease-specific targets based on post-translational modifications (PTMs)
- Development of therapeutic antibodies that selectively bind to disease-specific PTMs
- Focus on chronic diseases and cancer
- Aims to minimize off-target effects and maximize therapeutic impact